Sequenom's target practice

Through its genome screening technology, Sequenom Inc. has generated targets in 11 disease areas. Like many target companies, SQNM now has determined that it has more targets than capacity. Thus, SQNM believes that its first full disease area deal - an osteoporosis partnership with Procter & Gamble - may serve as a model for its plans to partner targets in other disease areas.

SQNM has targets in breast cancer, lung cancer, prostate cancer, melanoma, schizophrenia, Type II diabetes, obesity, dyslipidemia, hypertension, osteoarthritis and osteoporosis. The targets are generated by screening genomes from hundreds to thousands of well-phenotyped individuals using more than 28,000 SNP markers. ...